Significant Impurities, Safety Risks Found in Compounded Tirzepatide with B12, Eli Lilly Warns
summarizeSummary
Eli Lilly has issued a public warning regarding potential patient safety risks associated with compounded tirzepatide mixed with Vitamin B12. The company's testing revealed significant levels of an impurity resulting from a chemical reaction between tirzepatide and B12, and noted other critical safety issues in compounded knockoffs, including bacterial contamination. Lilly has notified the U.S. Food and Drug Administration (FDA) about these findings and is urging the agency to take action against unlawful mass compounding, including requesting recalls. This development is significant as tirzepatide (Mounjaro/Zepbound) is a major revenue driver for Lilly, and safety concerns, even with compounded versions, could impact public perception and demand for the legitimate product. Traders will be watching for FDA response and any potential impact on Lilly's market position.
At the time of this announcement, LLY was trading at $998.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $943.2B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.